Survival After Blood Transfusion in the French Administrative Regions of Burgundy and Franche-Comté
Completed
- Conditions
- Erythrocyte Transfusion for All Conditions
- Registration Number
- NCT02852993
- Lead Sponsor
- Centre Hospitalier Universitaire de Besancon
- Brief Summary
Red blood cell transfusion (RBC) is the main symptomatic treatment for severe anemia. RBC transfusion has proven its efficacy regarding mortality and morbidity, but it is not without side effects. The infectious side effects of transfusion are largely considered under control, non-infectious side effects are taking center stage. Seeking explanations for the beneficial and deleterious effects of RBC transfusions is necessary to ensure the safe and optimal use of this precious resource.
The investigators aim to study the impact of donor and RBC characteristics on patient survival.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 16099
Inclusion Criteria
- Aged 18 and over
- Erythrocyte Transfusion between 2007 and 2011
- Performed at the University Hospital of Besançon or Dijon
Exclusion Criteria
- Transfusion of any blood product prior to January 1st, 2007
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Survival 12 months
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (2)
Centre d'Investigation Clinique, CHU de Besançon
🇫🇷Besançon, France
Département d'information Médicale, CHU Dijon
🇫🇷Dijon, France